NUMI.TO Numinus Wellness (TSX) pre-market 16 Jan 2026: earnings could test liquidity
NUMI.TO stock trades at C$0.05 in pre-market activity on 16 Jan 2026 as investors position ahead of an earnings release scheduled for 19 Jan 2026. Volume is elevated at 989,752 shares versus an average of 184,378, highlighting short-term interest and thin liquidity. This earnings spotlight looks at valuation, cash metrics, and what the report must show to shift market sentiment before the TSX open.
NUMI.TO stock: pre-market snapshot and price action
Numinus Wellness (NUMI.TO) is quoted at C$0.05 with the daily range at C$0.05–C$0.05. Volume stands at 989,752 against an average of 184,378, giving a relative volume of 5.37 and signalling outsized activity ahead of earnings. The company’s market cap is approximately C$16,027,581.00 with 320,551,620 shares outstanding.
NUMI.TO stock: upcoming earnings and what to watch
Numinus reports on 19 Jan 2026 and the market will focus on revenue recognition mix, operating cash flow, and guidance for clinic volumes. The trailing EPS is -0.08 and the reported PE metric is negative at -0.63, so management commentary on margins and cash burn will drive immediate price moves. Investors should watch clinical or licensing updates that could affect near-term revenue visibility.
NUMI.TO stock: financials and valuation metrics
The balance metrics show a tight liquidity profile with a current ratio near 0.61 and cash per share of C$0.0028. Valuation ratios include price averages 50-day C$0.0465 and 200-day C$0.04381, year high C$0.125 and year low C$0.025. Key multiples are distorted by negative earnings: price-to-sales and price-to-book read as -3.58 and -9.44 respectively, underscoring a recovery-dependent valuation.
NUMI.TO stock: Meyka AI grade and forecast model
Meyka AI rates NUMI.TO with a score out of 100. Meyka AI rates NUMI.TO with a score of 65.87 out of 100 — Grade B — Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects C$0.08 in 12 months versus the current C$0.05, implying an upside of 60.00%. Forecasts are model-based projections and not guarantees.
NUMI.TO stock: liquidity, technicals and trading risks
Trading shows thin price bands and elevated short-term volume; the relative volume 5.37 increases execution risk. The 50-day average C$0.0465 sits slightly below current price and the 200-day C$0.04381 confirms the recent modest recovery. Expect gaps and wide spreads; limit orders are prudent given low nominal price and volatility.
NUMI.TO stock: sector context and near-term catalysts
Numinus operates in Healthcare (Medical – Care Facilities) where the sector average PE is approximately 14.40. NUMI.TO’s negative earnings place it outside peer valuation norms, so upside depends on operational progress and regulatory clarity. Near-term catalysts include the 19 Jan 2026 earnings release, potential clinical or licensing updates, and ETF flows such as holdings noted in PSIL that can affect sentiment source. Also see the U.S. quote context on Nasdaq for cross-listed activity source.
Final Thoughts
NUMI.TO stock enters the 19 Jan 2026 earnings window with price at C$0.05, thin liquidity, and high short-term volume. The report must show improved revenue mix, clearer clinic utilization trends, or a demonstrated path to reduce cash burn to shift the consensus. Meyka AI’s quantitative score (65.87/100, Grade B, Suggestion: HOLD) reflects mixed fundamentals and sector positioning. Our model projects a C$0.08 12-month target, implying +60.00% upside from today’s price, while a downside scenario to C$0.03 would entail -40.00%. These projections are model-based and not guarantees. Investors should weigh the company’s low cash-per-share (C$0.0028), current ratio 0.61, and negative earnings against potential clinical or licensing catalysts. For live quote updates and deeper metrics visit the Meyka stock page for NUMI.TO for real-time AI-powered market analysis Meyka NUMI.TO page.
FAQs
When will Numinus report earnings and what matters most
Numinus reports on 19 Jan 2026. For NUMI.TO stock investors, the key items are revenue recognition, clinic volumes, operating cash flow, and any guidance or licensing news that affects near-term revenue visibility.
What is Meyka AI’s short-term price outlook for NUMI.TO stock
Meyka AI’s forecast model projects C$0.08 in 12 months for NUMI.TO stock, implying roughly +60.00% from the current C$0.05. Forecasts are model-based projections and not guarantees.
How liquid is NUMI.TO stock and what trading risks exist
NUMI.TO stock shows elevated pre-market volume 989,752 with avg volume 184,378, but the low nominal price leads to wide spreads and execution risk. Use limit orders and smaller sizes to manage volatility.
What are the main valuation red flags for NUMI.TO stock
Numinus posts negative earnings (EPS -0.08) and distorted ratios such as price-to-book -9.44. The current ratio 0.61 and low cash per share C$0.0028 are liquidity concerns that weigh on valuation.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
